JP2019522461A5 - - Google Patents

Download PDF

Info

Publication number
JP2019522461A5
JP2019522461A5 JP2018558287A JP2018558287A JP2019522461A5 JP 2019522461 A5 JP2019522461 A5 JP 2019522461A5 JP 2018558287 A JP2018558287 A JP 2018558287A JP 2018558287 A JP2018558287 A JP 2018558287A JP 2019522461 A5 JP2019522461 A5 JP 2019522461A5
Authority
JP
Japan
Prior art keywords
seq
grna molecule
set forth
nucleotide sequence
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018558287A
Other languages
English (en)
Japanese (ja)
Other versions
JP7075597B2 (ja
JP2019522461A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031351 external-priority patent/WO2017193029A2/en
Publication of JP2019522461A publication Critical patent/JP2019522461A/ja
Publication of JP2019522461A5 publication Critical patent/JP2019522461A5/ja
Application granted granted Critical
Publication of JP7075597B2 publication Critical patent/JP7075597B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018558287A 2016-05-05 2017-05-05 デュシェンヌ型筋ジストロフィーを治療するためのcrispr/cas関連の方法および組成物 Active JP7075597B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332297P 2016-05-05 2016-05-05
US62/332,297 2016-05-05
PCT/US2017/031351 WO2017193029A2 (en) 2016-05-05 2017-05-05 Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy

Publications (3)

Publication Number Publication Date
JP2019522461A JP2019522461A (ja) 2019-08-15
JP2019522461A5 true JP2019522461A5 (enExample) 2020-06-25
JP7075597B2 JP7075597B2 (ja) 2022-05-26

Family

ID=60203369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018558287A Active JP7075597B2 (ja) 2016-05-05 2017-05-05 デュシェンヌ型筋ジストロフィーを治療するためのcrispr/cas関連の方法および組成物

Country Status (5)

Country Link
US (1) US20190134221A1 (enExample)
EP (1) EP3452498B1 (enExample)
JP (1) JP7075597B2 (enExample)
ES (1) ES2957660T3 (enExample)
WO (1) WO2017193029A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
EP3597741A1 (en) 2012-04-27 2020-01-22 Duke University Genetic correction of mutated genes
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
JP6929791B2 (ja) 2015-02-09 2021-09-01 デューク ユニバーシティ エピゲノム編集のための組成物および方法
CN108351350B (zh) 2015-08-25 2022-02-18 杜克大学 使用rna指导型内切核酸酶改善基因组工程特异性的组合物和方法
US11970710B2 (en) 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
EP4434589A3 (en) 2015-10-23 2025-05-14 President and Fellows of Harvard College Evolved cas9 proteins for gene editing
KR102787119B1 (ko) * 2015-11-30 2025-03-27 듀크 유니버시티 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
EP4275747A3 (en) 2016-07-19 2024-01-24 Duke University Therapeutic applications of cpf1-based genome editing
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
KR20200121782A (ko) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3728598A1 (en) * 2017-12-21 2020-10-28 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Nucleic acid sequence replacement by nhej
BR112020015617A2 (pt) * 2018-01-31 2021-01-05 The Board Of Regents Of The University Of Texas System Composições e métodos para correção de mutações da distrofina em cardiomiócitos humanos
US12152242B2 (en) 2018-04-23 2024-11-26 The Curators Of The University Of Missouri CRISPR therapy
US12351836B2 (en) 2018-05-04 2025-07-08 University Of Massachusetts Microhomology mediated repair of microduplication gene mutations
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020018918A1 (en) * 2018-07-19 2020-01-23 The Board Of Trustees Of The University Of Illinois Methods for exon skipping and gene knockout using base editors
BR112021007229A2 (pt) 2018-10-16 2021-08-10 Blueallele, Llc métodos para inserção dirigida de dna em genes
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
EP3966327A1 (en) * 2019-05-08 2022-03-16 Vertex Pharmaceuticals Incorporated Crispr/cas all-in-two vector systems for treatment of dmd
CN110499333A (zh) * 2019-08-01 2019-11-26 广州德赫生物科技有限公司 用于修复dmd基因突变的核酸序列及系统
AU2020357668A1 (en) * 2019-10-02 2022-03-10 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treatment of diseases caused by frame shift mutations
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
JP2023504190A (ja) * 2019-12-03 2023-02-01 デューク ユニバーシティ 遺伝子編集機構の脂質ナノ粒子送達のためのシステムおよび方法
EP4126224A4 (en) * 2020-04-27 2024-07-03 Duke University HIGH-THROUGHPUT SCREENING METHODS TO DISCOVER OPTIMAL GRNA PAIRS FOR CRISPR-MEDIATED EXON DELETION
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
EP4214317A2 (en) 2020-09-15 2023-07-26 Research Institute at Nationwide Children's Hospital Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy
US20230392132A1 (en) * 2020-10-21 2023-12-07 Duke University Dual aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy
US20240366604A1 (en) 2021-04-28 2024-11-07 Graviton Bioscience Bv Selective inhibitors of rock2 for the treatment of muscular dystrophy
WO2023039444A2 (en) * 2021-09-08 2023-03-16 Vertex Pharmaceuticals Incorporated Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
IL108449A (en) 1993-01-26 2011-09-27 Weiner David B Assemblies and methods for delivery of genetic material
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
CA2504593C (en) 2002-11-04 2016-08-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
KR102307280B1 (ko) * 2013-06-05 2021-10-01 듀크 유니버시티 Rna-가이드 유전자 편집 및 유전자 조절
CN105408730A (zh) * 2013-06-05 2016-03-16 纽约市哥伦比亚大学理事会 基于mems的量热计及其制造和使用
WO2016161380A1 (en) * 2015-04-01 2016-10-06 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
KR102787119B1 (ko) * 2015-11-30 2025-03-27 듀크 유니버시티 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법

Similar Documents

Publication Publication Date Title
JP2019522461A5 (enExample)
JP2018534950A5 (enExample)
JP2019524149A5 (enExample)
JP2017512767A5 (enExample)
JP2016538885A5 (enExample)
JP6799058B2 (ja) アレル選択的な遺伝子編集およびその使用
JP2020518276A5 (enExample)
US10822617B2 (en) RNA-targeting fusion protein compositions and methods for use
JP2021112211A5 (enExample)
JP2016521995A5 (enExample)
JP2017006120A5 (enExample)
JP2016116520A5 (enExample)
JP2024153629A5 (enExample)
JP2024038326A5 (enExample)
JP2020022459A5 (enExample)
AU2020310201A1 (en) RNA-targeting knockdown and replacement compositions and methods for use
JP2016537341A5 (enExample)
JP2017079759A5 (enExample)
JP2020524998A5 (enExample)
RU2016101198A (ru) Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов
JP2018143253A5 (enExample)
JP2019519219A5 (enExample)
JP2012528572A5 (enExample)
FR2737500B1 (fr) Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
JP2019521139A5 (enExample)